artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.
Company profile
Ticker
ARTL, ARTLW, ATLEW
Exchange
Website
CEO
Gregory D. Gorgas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KNIGHT KNOX DEVELOPMENT CORP., REACTIVE MEDICAL INC.
SEC CIK
Corporate docs
Subsidiaries
Artelo Biosciences Limited • Artelo Biosciences Corporation ...
ARTL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Departure of Directors or Certain Officers
8 Aug 23
EFFECT
Notice of effectiveness
17 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
S-3
Shelf registration
6 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Aug 21 | Aug 20 | Aug 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.64 mm | 2.64 mm | 2.64 mm | 2.64 mm | 2.64 mm | 2.64 mm |
Cash burn (monthly) | 1.03 mm | 374.75 k | 871.33 k | 847.17 k | 600.67 k | 658.67 k |
Cash used (since last report) | 7.01 mm | 2.56 mm | 5.95 mm | 5.79 mm | 4.10 mm | 4.50 mm |
Cash remaining | -4.37 mm | 78.81 k | -3.31 mm | -3.15 mm | -1.46 mm | -1.86 mm |
Runway (months of cash) | -4.3 | 0.2 | -3.8 | -3.7 | -2.4 | -2.8 |
Institutional ownership, Q2 2023
68.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 82.14 mm |
Total shares | 2.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kingsbrook Partners | 800.00 k | $584.00 k |
Alpha Capital Anstalt | 784.01 k | $572.00 k |
Bigger Capital Fund L P | 450.00 k | $329.00 k |
Iroquois Capital Management | 100.00 k | $52.00 k |
Verition Fund Management | 27.30 k | $2.21 mm |
Two Sigma Advisers | 20.56 k | $40.92 mm |
Alpine Global Management | 14.10 k | $1.00 k |
Geode Capital Management | 13.71 k | $27.55 mm |
Tower Research Capital | 4.65 k | $9.26 mm |
JPM JPMorgan Chase & Co. | 304.00 | $611.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 85,000 | 131.75 k | 85,000 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 90,334 | 140.02 k | 90,334 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 38,340 | 59.43 k | 38,340 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 55,634 | 86.23 k | 55,634 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 5,000 | 7.75 k | 5,000 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.15 | 85,000 | 267.75 k | 0 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.45 | 90,334 | 853.66 k | 0 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 22.8 | 38,340 | 874.15 k | 0 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 39.9 | 55,634 | 2.22 mm | 0 |
28 Feb 24 | Gorgas Gregory D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 29.85 | 5,000 | 149.25 k | 0 |
News
HC Wainwright & Co. Maintains Buy on Artelo Biosciences, Maintains $5 Price Target
2 Apr 24
Artelo Biosciences Earlier Reported Q4 EPS $(0.99) Misses $(0.56) Estimate
25 Mar 24
Recap: Artelo Biosciences Q4 Earnings
25 Mar 24
Artelo Biosciences FY23 EPS $(3.14) Vs $(3.56) YoY
25 Mar 24
Artelo Biosciences Has Been Granted European Patent Number EP3723752 Titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)"
20 Mar 24